There are numerous proven treatment procedures for cancer. Since every tumor disease is different, it must be carefully weighed up which procedure seems most sensible medically and personally for a patient and in which order to proceed.
For this purpose, 14 tumor conferences (also known as tumor boards) are held regularly at Vivantes, bringing together experts from different medical fields to jointly agree on the best possible treatment for each patient. In a tumor conference, internists (hematologists/oncologists), radiation therapists, surgeons, pathologists and radiologists as well as doctors from other specialties regularly consult with each other. Together, they analyze the patient's medical history, the available examination results and each contribute their specialist knowledge in order to develop a tailored solution for the individual treatment steps. This is achieved across all sites by modern technologies in the form of videoconferencing.
Close cooperation within the network plays an important role at Vivantes - even beyond the hospital: Doctors in private practice also take part in tumor conferences in order to continue the treatment together and in a coordinated manner. Aspects of data protection are taken into account. The interdisciplinary tumor conferences thus form the heart of the care of our patients.
More than 110 hospitals, departments and institutes participate in the three Vivantes oncology centers in order to offer cancer treatment at the highest level in your neighborhood. Interdisciplinary therapy planning and care takes place at the centers. All physicians cooperate with the specialized departments, so that patients can reach an experienced cancer specialist in the shortest possible time, regardless of the department that first provides care. Our centers, certified by the German Society for Hematology and Medical Oncology (DGHO), as well as the German Cancer Society (DKG), guarantee the best possible care for all cancers.
In Vivantes' three oncology centers, more than 10,000 patients with cancers of the entire oncological spectrum are treated each year.
In addition to providing medical patient care, many physicians are involved in medical science, university teaching, clinical research and scientific societies. Particular emphasis is placed on conducting clinical trials to investigate the efficacy of new therapies.
Vivantes has established the Directorate of Clinical Research and Academic Teaching to promote and coordinate research and science within the Group. This is where scientific activities are bundled and supported.
The development of new active substances for the treatment of cancer is a long process, and only after a number of studies does a drug receive approval to be used in cancer therapy. Clinical trials are an indispensable part of this process. These are used to scientifically prove the efficacy of a new drug or a new therapeutic procedure. Only after this proof has been provided does the new active ingredient or the new therapy procedure receive its approval and can be made available to affected patients.
In Germany, there are strict requirements for conducting clinical trials. For example, possible side effects and effects on humans must already be investigated in preclinical experiments. This is followed by further testing in humans in three phases, in which the effect, dosage and tolerability of the new active ingredient are investigated step by step under close observation.
By participating in these studies, we give our patients the opportunity to benefit from new therapies on a strictly voluntary basis. This is an important contribution to scientific progress in cancer care for current and future patients.
Health Services Research
Health services research is concerned with the study of health and health care. This includes both medical and non-medical measures. This may involve the analysis of existing structures or the introduction of new methods and measures.
Oncology in particular has been characterized in recent years by huge advances and accompanying gratifying improvements in therapies. At the same time, the new therapeutic options not only pose new challenges for the healthcare system in financial terms, but also structurally and in terms of implementation, these developments will require the ongoing further development of healthcare structures.
At the same time, especially in the complex and protracted therapy of oncological diseases, further offers in addition to the therapeutic measures are of particular importance. The introduction or improvement of such additive measures can often achieve a great deal in terms of quality of life and therapeutic success.
Health services research is characterized by its direct relation to the therapy and care of patients. As a result, the results of studies in this field often have a more direct impact on the field of research and the lives of patients.